Definition

A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell co-stimulatory receptor CD2, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/anti-CD3/anti-CD2 trispecific antibody PIT565 targets and binds to CD3 and CD2 on T cells and CD19 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.